Finanzen von AC Immune AG (ACIU)ACIUAC Immune AG

Evaluating the bottom line, AC Immune AG maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 7.89%, while the net margin is 12.40%. These profitability ratios, combined with a Return on Equity (ROE) of -78.53%, provide a clear picture of how effectively ACIU converts its operational activities into shareholder value.

In the context of the broader market, ACIU competes directly with industry leaders such as AMRN and IMRX. With a market capitalization of $269.45M, it holds a leading position in the sector. When comparing efficiency, ACIU's gross margin of 100.00% stands against AMRN's 35.51% and IMRX's N/A. Such benchmarking helps identify whether AC Immune AG is trading at a premium or discount relative to its financial performance.

AC Immune has shown a significant recovery in net income, achieving $2.4 million in Q2 2026, compared to substantial losses in previous quarters. The gross margin remains strong at 100%, indicating effective cost management despite the volatility in revenue.